Skip to main content
. 2010 Mar 12;15(3):246–252. doi: 10.1634/theoncologist.2009-0243

Figure 1.

Figure 1.

Pathologic complete response (pCR) rate according to alkylating agent dose. (A): Patients with p53-mutated tumors. (B): Patients with wild-type p53 tumors.

Abbreviations: ddEC, dose-dense epirubicin and cyclophosphamide; E, single-agent epirubicin; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide.